Allogeneic hematopoietic stem cell transplantation for multiple myeloma: Curative but not the standard of care

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 720-726

  Koehne, Guenther ^a   Giralt, Sergio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

allogeneic hematopoietic stem cell transplantation; multiple myeloma; posttransplantation immunotherapy

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CANCER TESTIS ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELPHALAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CENTER; CANCER PATIENT; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION 14; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; CONFIDENCE INTERVAL; DISEASE CONTROL; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; GENE SILENCING; GRAFT REJECTION; HEALTH CARE QUALITY; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; REVIEW; SALVAGE THERAPY; SIBLING; T LYMPHOCYTE; WHOLE BODY RADIATION;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MELPHALAN; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; RISK; STANDARD OF CARE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84868200827     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328358f619     Document Type: Review

References (41)

1. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991; 325:1267-1273.
2. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13:1312-1322.
3. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356:1110-1120.
4. Rosiñ ol L, Pé rez-Simó n JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reducedintensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112:3591-3593;
5. Vesole DH, Zhang L, Flomenburg N, et al. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant 2009; 15:83-91.
6. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12:1195-1203.
7. WeaverC, Zhen B,Schwartzberg L, et al. Phase I-II evaluation of rapid sequence tandem high dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 1998; 22:245-251.
8. Gore M, Selby P, Viner C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet Oncol 1989; 2:879-882.
9. Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction thearpy in patients with newly diagnosed multiple myeloma. Cancer 2011; 118:1585-1592.
10. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366:1759-1769.
11. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1770-1781.
12. Attal MM, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1782-1791.
13. Barlogie B, Kyle R, Anderson K, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24:926-936.
14. Bashir Q, Khan H, Orlowski R, et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012; 87:272-276.
15. Björkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced intensity conditioning allogeneic stem-cell transplantation verus autologous transplantation in myeloma: long-term follow up. J Clin Oncol 2011; 29: 3016-3022.
16. Rajkumar SV, Kyle R. Multiple myeloma: diagnose and treatment. Mayo Clin Proc 2005; 80:1371-1382.
17. Greipp P, San Miguel J, Durie B, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-3420.
18. Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1. Br J Haematol 2004; 127:280-284.
19. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and-17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106:2837-2840.
20. Dimopoulos M, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010; 24:1769-1778.
21. Kobayashi T, Kuroda J, Shimura K, et al. Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. Int J Hematol 2010; 92:579-586.
22. van de Donk NW, Lokhorst HM, Dimopoulos M, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011; 37:266-283.
23. Kumar SK, Lee J, Lahuerta J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26:149-157.
24. de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008; 41:953-960.
25. Patriarca F, Einsele H, Spina F, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant 2012; 18:617-626.
26. El-Cheikh J, Crocchiolo R, Boher J, et al. Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. Eur J Haematol 2012; 88:497-503.
27. Devine SM, Carter S, Soiffer RJ, et al. Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303: low risk of chronic graftversus-host disease and relapse associated with T-cell depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011; 17:1343-1351.
28. Boyiadzis M, Klein JAM, Arora M, et al. Impact of chronic GVHD on late relapse, treatment related mortality and survival after allogeneic hematopoietic cell transplantation for hematological malignancies. Biol Blood Marrow Transplant 2012; abstract 19; 18(2).
29. Koehne G, Landau H, Hassoun H, et al. T-cell depleted allogeneic hematopoietic stem cell transplantation with busulfan, melphalan, and fludarabine conditioning followed by post transplantation donor lymphocyte infusions for patients with relapsed multiple myeloma and high-risk cytogenetics. ASH Annual Meeting [abstract]. Blood 2011; 118:abstr 1992.
30. Lokhorst HM, Schattenberg A, Corneliseen J, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outocme. J Clin Oncol 2000; 18:3031-3037.
31. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26:1179-1184.
32. Alyea E, Weller E, Schlossman R, et al. T-cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001; 98:934-939.
33. Kroeger N, Badbaran A, Lioznov M, et al. Posttransplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009; 37:791-798.
34. Tyler E, Jungbluth A, O'Reilly RJ, Koehne G. WT1-specific immune responses in patients with high-risk multiple myeloma undergoing allogeneic T cell depleted hematopoietic stem cell transplantation followed by donor lymphocyte infusions. ASH Annual Meeting 2011. Blood 2011; 118:abstr 1993.
35. Boon T, Old L. Cancer tumor antigens. Curr Opin Immunol 1997; 9:681-683.
36. Jungbluth A, Ely S, DiLiberto M, et al. The cancer-testis antigens CT7 (MAGE-C') and MAGE-A3/6 are commonly expressed in multiple myeloma and correlated with plasma-cell proliferation. Blood 2005; 106:167-174.
37. Dhodapkar M, Osman K, Teruya-Feldstein J, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7 and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003; 3:9-17.
38. Atanackovic D, Arfsten J, Cao Y, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109:1103-1112.
39. Atanackovic D, Hildebrandt Y, Jadczak A, et al. Cancer-testis antigens MAGEC1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010; 95:795-893.
40. Nardiello T, Achim A, Jungbluth A, et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of bax and maintenance of survivin. Clin Cancer Res 2011; 17:4309-4319.
41. Anderson L, Cook D, Yamamoto T, et al. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother 2011; 60:985-997.